ArticleExperimental & molecular medicine2026
Regulation of PKM2 expression and function by GLIS3 during metabolic reprogramming in polycystic kidneys.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Deficiency in GLI-similar 3 (GLIS3) in humans and mice causes polycystic kidney disease (PKD). We previously reported that Glis3-knockout (KO) kidneys undergo metabolic reprogramming and remain more reliant on aerobic glycolysis. Here, to understand the mechanism by which GLIS3 controls this process, we analyzed its role in regulating glycolytic gene expression using transcriptomics and cistromics. Transcriptomic analysis revealed increased expression of key glycolytic genes and reduced expression of several gluconeogenic genes in Glis3-KO compared with wild-type kidneys. Chromatin immunoprecipitation followed by sequencing analysis showed that many of these genes were directly regulated by GLIS3 in coordination with the transcription factor, HNF-1B. Pkm emerged as a key upregulated glycolytic GLIS3 target gene, which via alternative splicing generates two protein isoforms, PKM1 and PKM2. Expression of Pkm and the dimeric form of PKM2, which promotes aerobic glycolysis, was elevated in Glis3-KO kidneys, whereas exogenous GLIS3 expression in primary Glis3-KO renal epithelial cells suppressed Pkm expression. Phosphorylation of PKM2 at Y105 and S37, which stimulate dimer formation, nuclear localization and aerobic glycolysis, is increased in Glis3-KO kidneys, consistent with a role for PKM2 in metabolic reprogramming and cyst formation. Consistent with this, siRNA-mediated knockdown of PKM2 in Glis3-KO renal epithelial cells suppressed spheroid growth and glycolytic activity. In addition, pharmacological inhibition of PKM2 with compound 3K in GLIS3-deficient spheroid cultures and Glis3-KO kidneys significantly reduced spheroid size, cyst number and cystic area. Our study identifies GLIS3 as a novel regulator of glycolysis and PKM2 function, whose dysregulation contributes to metabolic reprogramming and cystogenesis in Glis3-KO kidneys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.